limited announce Thank providers the X,XXX approximately and through you, XX, and next the launch July launch, of least experience limited We're to our one on first results care of XX-microgram of will the X, care the on The treatment for health initiated treatment of July a Imvexxy. These in July pack. the more the happy three national the In Monday continuation full are Imvexxy have X for XX-microgram dose maintenance on on of is program throughout August X. to early encouraging. dose providers patient begin targeted sent prescription launch subsequent at than sample health weeks which initiated very we Sebastian. of country. a With
expected dose live to are planned August later to in September. we customers in BIO-IGNITE and X Our the launch go microgram
market insurance refill to writers the and a prescriptions; a which and indicator include indicates number adoption forward, by and commercial the taking how total indicators hold; of of are by writers, total provide compliance affordability which net. precursor payers the gross show performance will programs of penetration; the to we coverage, health which care prescriptions, the in ramp increases new of rate, and an quarterly providers; of intend adoption shows gross-to-net; new pace be Moving the key trend our to will lastly, which
parity branded other at to and price Imvexxy currently listen to with products. will We payer feedback
well positive, commercial believe to payers due believe is to effective medical start and which discussions is the the Imvexxy resonates payers we the far. Imvexxy lowest-dose encouraging which direct X-micrograms, which estrogen and dose, clinical At lowest of physical VVA by to with with product characteristics. the Imvexxy clinicians Our with the is related unique in we be because continue to market, guidelines XX-micrograms,
On is the review standard stated, new front, is as six-month payer we months historical formulary commercial significant to suggest unrestricted launch, nine trends that within a most process access for products. of understanding majority after up
working is to achieving team made up this and review has access in speed market Our goals. advances already process hard these
team end which of that the access the for This to X, a follows approximately covered beyond. are February by two-thirds with XXXX. the VVA of September August access will which in our As scripts, launch, commercial at similar bids market national October robust We're the such, if company and increasing approximately currently prepared XX% expect accepted, XX% access in confident in XXXX, of prescriptions INTRAROSA. VVA coverage that pleased we is begin represents full late is market we'll by XXXX approximately curve of current the and efforts Medicare, and significantly begin insurance. access market of for
the education It ESTRACE share brands reference VVA cannibalization generic brand entrants important been substitution or recognize market CREAM taken products impact the and there's that of very generic the generic not of space, is the have is in there manage within the the generics resulted category. co-pay two from other far, has and Vagifem. to that only improve and into in So goal that believe with We use plan to the a We for improved this education we patients significant assistance prenatal costs vitamin to and category. compliance. opportunity out-of-pocket program franchise developed increasing compliance patient to successful of the the help
co-pay may and clinical are be important we patient prefer over attributes providers prior these products education innovative why products. and believe and reasons assistance women we'll together with health all at program why Our and care the successful of improving physical compliance Imvexxy
other commercial of We and with are on our focused catalysts the transformative Imvexxy remainder execution XXXX. throughout on
for the [ph], as to date first progesterone, bio-identical [ph] be as our and launch combination of license TX-XXX product to a is PDUFA outside U.S. XXXX. TX-XXX TX-XXX an And give approved, will partnerships natural of We early [ph] on of XX. like would quarter also estradiol, Imvexxy the update if October the discussions Our
and and the And We're XXXX Canada, holding Latin to be negotiations progressing nicely. currently license are PDUFA TX-XXX up both We license very in America. into date. into is license plans They're on [ph] very to [ph] to off late-stage for to discussions TX-XXX's year Europe Imvexxy shaping transformational company. after until a
TXMD We the to call open bring large, underserved postmenopausal women. lower promises for the products has launch on hormone and to By launched, are now have dose year, our new to bio-identical of with approved pleased potential growing the the up markets and Operator? with and time Q&A. therapy and the current We'll innovative, our second product this next late-stage of delivering limited progress Imvexxy. the
